ZOVOO
10.12.2021 09:28:14 CET | Business Wire | Press release
ZOVOO , founded in 2019 and emerging as a dark horse in the electronic cigarette industry, recently launched its latest product Dragbar and achieved a sales milestone of over 1,000,000 pieces in the global market in less than one month, fully demonstrating the extraordinary strength of ZOVOO .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211210005123/en/
User-oriented and differentiated to meet market demand
According to ZOVOO' s global sales analysis, ZOVOO had an impressive performance in Southeast Asia, North America and Europe, which is attributable to not only Dragbar' s excellent capability, but also the ZOVOO team's in-depth and detailed market analysis of different regions.
Dragbar' s innovation and research team employed polymer fibers and ergonomic lip sensation design to address the consumers' most-concerned issues such as oil leakage and dry hit, while also ensuring the taste and recovery of the product. Using the most popular double injection molding process and the collision of extremely vibrant colors, the high-quality product is aesthetically attractive and tasteful, and soon gained the recognition of the consumers.
Product preference varies in different markets, so the team made in-depth investigations on product appearances and sizes and provided different series of Dragbar to cater to users in different regions, eventually achieving sales performance that was in line with the target of the ZOVOO team.
Creating amazing products with extreme craftsmanship
The ZOVOO design team, with its decade-long history, consists of senior creative elites, concept artists, visual designers and technical engineers. As ZOVOO 's first product for the overseas market, Dragbar cost the design team a whole year to finish. Even after thousands of adjustments, tests, and appearance improvements, the team did not start mass production until it was 100% confident with the final product.
In addition, since the founding of ZOVOO , the team has been focused on technology, constantly making breakthroughs and pursuing new patents and new technologies. During the long process ranging from research and development to design, production, and testing before the launch of each product, the innovation and research team is particular about every detail of the product, so as to bring comfortable and safe experience to the consumers.
Dragbar' s sales volume of 1,000,000 pieces achieved in a short period of time fully demonstrated the ZOVOO team's accurate insight into the users' needs, its excellent research and development capabilities, as well as its forward-looking product design strength. With the excellent performance of Dragbar, ZOVOO has successfully entered markets in more than 50 countries and regions in North America, Europe and Southeast Asia. In the future, the ZOVOO team will continue to develop new products in line with market trends to meet the users' new needs.
About ZOVOO
ZOVOO has established strategic partnerships with ICCPP manufacturers on a basis of mutual trust. ZOVOO enables its sustainable supply chain management by supporting safety standards, social values and environment-friendliness. With the motto of "Creating is Endless", ZOVOO is committed to adding inspirations to the colorful life of people with technology, and seeking partners globally to better serve the consumers.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical. The product is only intended for adult smokers of legal purchase age.
ZOVOO Official Website: https://www.izovoo.com/
IG: https://www.instagram.com/zovoo_tech/
Facebook: https://www.facebook.com/zovootechofficial
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005123/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom